Natumin Pharma acquires Ambria Dermatology - December 6, 2009

Natumin Pharma AB and P.U.L.S. recently announced that Natumin Pharma has acquired Ambria Dermatology AB for SEK 32 million.

Keystone Symposia Announces 52 Conferences for its 2010 Season - October 2, 2009

SILVERTHORNE, CO – September 28, 2009 – Keystone Symposia on Molecular and Cellular Biology is featuring 52 conferences in a diverse array of disciplines in its 39th meeting season, which runs from October 2009 through June 2010.

Applied Biosystems Launches New Genomic Analysis Tools that Simplify Disease Research - September 16, 2009

Applied Biosystems, part of Life Technologies Corporation, has announced the launch of genomic analysis tools that will help researchers in studies that associate genetic variation with specific diseases. These new tools, known as the MeltDoctor™ High-Resolution Melt (HRM) Reagents, are for research use only and are part of a PCR-based workflow that enables researchers to cost-effectively scan DNA from a variety of biological sample types to detect the smallest genetic variations among samples.

TFS and Karolinska University Hospital prolongs their early clinical development partnership until 2016 and expands the research facilities - September 9, 2009

TFS Trial Form Support International (TFS) and Karolinska University Hospital has as of May 25th, 2009 prolonged their public private partnership until 2016 and expanded their early clinical research unit at Karolinska Trial Alliance (KTA) with additional 850 square meters and 16 overnight beds. The partnership comprises early clinical development with studies conducted at the integrated research unit at KTA.

Neublastin enters Phase I clinical development as a novel treatment for neuropathic pain
- September 3, 2009

NsGene A/S today announced that Neublastin, a proprietary therapeutic protein that NsGene has out-licensed to Biogen Idec [NASDAQ: BIIB] in the field of peripheral nervous system disorders, has entered into Phase I clinical development for the treatment of neuropathic pain.

Neovacs appoints Piers Whitehead as VP of Corporate Development, to lead partnering effort for maturing pipeline of proprietary immunotherapeutics - September 2, 2009

Paris, September 2, 2009 Neovacs, a biotechnology company developing proprietary immunotherapeutics for autoimmune and chronic diseases, announced today that Piers Whitehead has joined the Company`s management team as VP Corporate Development.

Small volume DNA quantification with Tecan’s Infinite® 200 NanoQuant
- September 1, 2009

Scientists from Affymetrix, Inc., a world-leading supplier of microarray equipment and assays, have compared the performance of Tecan’s Infinite 200 NanoQuant multimode microplate reader with other instruments on the market for low volume DNA concentration analysis. Dr Jim Collins, Director of Assay Development, explained: “We have recently developed a new generation of general cytogenetic assay, requiring precise spectrophotometric quantification of small volumes of DNA.

VTT launches large European cooperation project for developing manufacturing method for biofuel - August 20, 2009

VTT Technical Research Centre of Finland has started a large European project, combining the forces of European research institutes and companies for developing the next generation of biofuel. The NEMO project, which has received funding of EUR 5.9 million from the EU, is aimed at developing manufacturing methods for liquid biofuel from agricultural and forestry waste, such as straws and wood chips.

PharmaEssentia's long-acting HC/BV drug candidate P1101 (PEG-P-IFN-alpha-2b) receives FDA IND approval - August 4, 2009

TAIPEI, Taiwan -- Drug development company PharmaEssentia Corp.'s third-generation interferon drug candidate P1101 (PEG-P-IFN-alpha-2b) for the treatment of hepatitis B and C, has received US FDA IND approval, with Phase I clinical trials in both Canada and Taiwan set to begin in the third quarter of 2009.

The announcement was made in Taipei on Tuesday, with PharmaEssentia Founder and CEO Dr. KC Lin stating that the US FDA had sent the company its formal IND approval notice that it had reviewed and accepted the PK/PD and other pre-clinical data submitted in its IND application.

Researchers of VTT, the University of Turku and the University of Heidelberg discover new information on spreading of cancer - July 01, 2009

A joint research group of VTT Technical Research Centre of Finland and the University of Turku, led by Professor Johanna Ivaska, has discovered a mechanism lung cancer cells use when spreading into the body to form metastases. The study has been published in Science Signaling on 30th June 2009. In cooperation with the University of Heidelberg, they have also found a factor controlling the spreading of several different cancer types. The common feature in both findings is that they explain the lethal ability of cancer cells to “start running” and spread from the original tumour to other parts of the body.

New chronotherapy for adrenal insufficiency - June 29, 2009

DuoCort publishes data from its Phase I study for the rare and life threatening disease adrenal insufficiency. The release profile of DuoCort’s new form of treatment with once-a-day hydrocortisone dosing closely resembles the physiological secretion pattern. The data is published today in the European Journal of Endocrinology, a leading scientific journal for endocrinology.